am-630 and Diarrhea

am-630 has been researched along with Diarrhea* in 1 studies

Other Studies

1 other study(ies) available for am-630 and Diarrhea

ArticleYear
Modulation of the endocannabinoid system by the fatty acid amide hydrolase, monoacylglycerol and diacylglycerol lipase inhibitors as an attractive target for secretory diarrhoea therapy.
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2017, Volume: 68, Issue:4

    Secretory diarrhoea is a leading cause of mortality and morbidity worldwide. Our aim was to characterize the effect of inhibition of selected enzymes involved in the synthesis or degradation of endocannabinoids on electrolyte equilibrium in the mouse colonic tissue. The aim of this study was to evaluate the effects of PF-3845, JZL-184 and RHC-80267, as inhibitors of fatty acid amide hydrolase (FAAH), monoacylglycerol (MAGL) and diacylglycerol lipase (DAGL), respectively on epithelial ion transport in isolated mouse colon stimulated by forskolin (FSK), veratridine (VER) and bethanechol (BET). Next, colonic tissue was co-incubated with selected inhibitors and cannabinoid receptor antagonists: AM 251 and AM 630 (CB

    Topics: Amidohydrolases; Animals; Benzodioxoles; Cannabinoid Receptor Agonists; Cannabinoid Receptor Antagonists; Cyclohexanones; Diarrhea; Endocannabinoids; Enzyme Inhibitors; Indoles; Lipoprotein Lipase; Male; Mice; Monoglycerides; Piperidines; Pyrazoles; Pyridines; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2

2017